Beta Bionics, Inc. (BBNX)
| Market Cap | 1.15B +14.7% |
| Revenue (ttm) | 119.01M +52.5% |
| Net Income | -72.97M |
| EPS | -1.65 |
| Shares Out | 52.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,204,819 |
| Open | 21.30 |
| Previous Close | 21.43 |
| Day's Range | 21.10 - 22.16 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 22.40 (+2.33%) |
| Earnings Date | Oct 27, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for BBNX stock is "Buy." The 12-month stock price target is $22.4, which is an increase of 2.33% from the latest price.
News
Kaplan Fox Urges Investors of Beta Bionics, Inc. (NASDAQ: BBNX) with Significant Losses to Seek a Leadership Role Before November 3, 2026
NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX...
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its com...
Kaplan Fox Reminds Beta Bionics, Inc. (NASDAQ: BBNX) Investors Seeking Recovery of the Lead Plaintiff Deadline on November 3, 2026
NEW YORK, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX...
Beta Bionics 7.652M share Spot Secondary priced at $17.25
The deal size was increased to $150M in common stock from $125M in common stock and priced within the $17.00-$17.50 range. JPMorgan, Piper Sandler, Wells Fargo and Leerink acted as…
Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price t...
Beta Bionics $125M Spot Secondary; price range $17.00-$17.50
JPMorgan, Piper Sandler, Wells Fargo and Leerink are acting as joint book running managers for the offering.
Beta Bionics announces $125M common stock offering
Beta Bionics (BBNX) announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125M of shares of its common stock.
Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and oth...
Beta Bionics price target raised to $23 from $22 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Beta Bionics (BBNX) to $23 from $22 and keeps a Buy rating on the shares. The firm is citing the…
Beta Bionics price target raised to $16 from $14 at Baird
Baird raised the firm’s price target on Beta Bionics (BBNX) to $16 from $14 and keeps a Neutral rating on the shares.
Beta Bionics price target raised to $25 from $22 at UBS
UBS raised the firm’s price target on Beta Bionics (BBNX) to $25 from $22 and keeps a Buy rating on the shares. Beta Bionics’ FDA clearance of the Mint patch…
Beta Bionics price target raised to $20 from $18 at BofA
BofA raised the firm’s price target on Beta Bionics (BBNX) to $20 from $18 and keeps a Neutral rating on the shares after the company announced its patch pump, Mint,…
Beta Bionics price target raised to $27 from $24 at Leerink
Leerink analyst Mike Kratky raised the firm’s price target on Beta Bionics (BBNX) to $27 from $24 and keeps an Outperform rating on the shares.
Beta Bionics Announces FDA Clearance of Mint™, the Company's Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Dr...
Senseonics partners with Beta Bionics to integrate Eversense 365
Senseonics (SENS) announced a partnership with Beta Bionics (BBNX). The companies are collaborating to integrate Eversense 365 CGM with Beta Bionics’ iLet Bionic Pancreas automated insulin delivery sy...
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancre...
Grabar Law Office Investigates Claims on Behalf of Long-term Shareholders of Beta Bionics, Inc. (BBNX)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX). What is This Investigation...
BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With Large Losses in Beta Bionics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acqui...
Beta Bionics initiated with a Market Perform at William Blair
William Blair initiated coverage of Beta Bionics (BBNX) with a Market Perform rating. The firm believes Beta has a solid pipeline, led by its expected entry into the patch pump…
Beta Bionics price target raised to $18 from $15.50 at BofA
BofA analyst Travis Steed raised the firm’s price target on Beta Bionics (BBNX) to $18 from $15.50 and keeps a Neutral rating on the shares. The firm raised its multiple…
Beta Bionics price target raised to $15.50 from $13 at BofA
BofA raised the firm’s price target on Beta Bionics (BBNX) to $15.50 from $13 and keeps a Neutral rating on the shares. Following the Q2 report, the firm applies a…
Beta Bionics price target lowered to $30.40 from $32 at Ladenburg
Ladenburg analyst Jeffrey Cohen lowered the firm’s price target on Beta Bionics (BBNX) to $30.40 from $32 and keeps a Buy rating on the shares.
Beta Bionics Earnings Call Transcript: Q2 2026
Q2 2026 saw 38% year-over-year revenue growth to $32M, with gross margin expanding to 59% and strong new patient starts, especially from those switching from multiple daily injections. The company advanced its innovation pipeline, raised gross margin guidance, and remains well-capitalized for future growth.
Beta Bionics Earnings release: Q2 2026
Beta Bionics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Beta Bionics Slides: Q2 2026
Beta Bionics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.